Abstract | BACKGROUND: OBJECTIVE: To establish the safety and tolerability of fexofenadine hydrochloride in children aged 6 months to 2 years in 2 studies (T/3001 and T/3002). METHODS: Both studies had a multicenter, randomized, placebo-controlled design. Mean treatment duration was 8 days. Subjects were randomized (T/3001, n = 174; and T/3002, n = 219) to twice-daily fexofenadine hydrochloride, 15 or 30 mg, or placebo mixed with a standard vehicle. RESULTS: In the combined population, the incidence of treatment-emergent adverse events (TEAEs) was comparable between groups (placebo, 48.2% [96/199]; fexofenadine hydrochloride, 15 mg, 40.0% [34/85]; and fexofenadine hydrochloride, 30 mg, 35.2% [38/108]). Vomiting was the most common TEAE (placebo, 13.6%; fexofenadine hydrochloride, 15 mg, 14.1%; and fexofenadine hydrochloride, 30 mg, 5.6%). Most TEAEs were unrelated to study medication, as evaluated by investigators; those possibly related to study medication were mild or moderate in intensity. No clinical differences were seen between fexofenadine and placebo for vital signs, electrocardiographic results, or physical examination results. CONCLUSION:
Fexofenadine hydrochloride, 15 or 30 mg, given for a mean duration of 8 days is well tolerated, with a good safety profile, in children aged 6 months to 2 years.
|
Authors | Frank C Hampel, Barbara Kittner, Julius H van Bavel |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 99
Issue 6
Pg. 549-54
(Dec 2007)
ISSN: 1081-1206 [Print] United States |
PMID | 18219837
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Histamine H1 Antagonists, Non-Sedating
- Terfenadine
- fexofenadine
|
Topics |
- Administration, Oral
- Blood Pressure
(drug effects)
- Body Temperature
(drug effects)
- Body Weight
(drug effects)
- Child, Preschool
- Electrocardiography
(drug effects)
- Histamine H1 Antagonists, Non-Sedating
(administration & dosage, adverse effects)
- Humans
- Infant
- Male
- Rhinitis, Allergic, Perennial
(drug therapy)
- Statistics, Nonparametric
- Terfenadine
(administration & dosage, adverse effects, analogs & derivatives)
|